source
- Novo Nordisk's GLP-1 pill shows blood-sugar reduction in teens with type 2 diabetesNovo Nordisk reported results from a study evaluating its oral GLP-1 therapy, Rybelsus, in adolescents with type 2 diabetes. The trial enrolled participants aged 10-17 who took the pill for roughl…
- Roche remains bullish on giredestrant despite first-line trial setbackRoche's CEO Thomas Schinecker said the company still expects its investigational oral breast cancer therapy giredestrant to generate strong sales, potentially surpassing Herceptin. The optimism fo…